The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly ...
Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...
The MarketWatch News Department was not involved in the creation of this content. -- Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated ...
Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammation MB0109 demonstrated ...
Learn how targeted-release budesonide treats IgA nephropathy, cutting proteinuria and slowing GFR decline with fewer steroid side effects. When are you utilizing endothelin antagonists, complement ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...
Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results